SEC Form 4 · accession 0001209191-18-004994
Biohaven Pharmaceutical Holding Co Ltd. · BHVN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gregory Bailey
Director
Period of report
Jan 19, 2018
Accepted (ET)
Jan 23, 2018 · 6:57 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001689813
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF2 | Jan 19, 2018 | S | 6,812 | $29.20 | D | 2,583,289 | D | |
| Common SharesF3 | Jan 19, 2018 | S | 17,249 | $30.18 | D | 2,566,040 | D | |
| Common SharesF4 | Jan 19, 2018 | S | 15,939 | $31.08 | D | 2,550,101 | D | |
| Common SharesF5 | Jan 22, 2018 | S | 9,000 | $32.51 | D | 2,541,101 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the record holder of the securities on August 19, 2017.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.75 - $29.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.75 - $30.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.75 - $31.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form 4.
- F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.50 - $32.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (5) to this Form 4.